Pharmacology  ·  Antiparasitic Drugs

Antimalarial Agents

Life cycle targets, drug mechanisms, prophylaxis selection, toxicity, and resistance

Abbreviations: G6PD = glucose-6-phosphate dehydrogenase  ·  ACT = artemisinin-based combination therapy  ·  QTc = corrected QT interval  ·  pfcrt = P. falciparum chloroquine resistance transporter  ·  DHFR = dihydrofolate reductase  ·  FDA = US Food and Drug Administration

Life Cycle Drug Targets
Causal Prophylactics
Kill Hepatic Schizonts Before Blood Stage
  • Atovaquone-proguanil, doxycycline, primaquine — act on liver stage
  • Prevent blood-stage infection entirely — fewer post-travel days required; stop 7 days after leaving endemic area
  • No need for the 4-week tail — drug eradicates hepatic parasites before they can mature into erythrocytic forms
Suppressive Prophylactics
Kill Blood-Stage Parasites Only
  • Chloroquine, mefloquine — blood-stage schizonticidal only
  • Continue 4 weeks after leaving endemic area — liver-stage parasites mature into blood-stage during this window; stopping early allows post-travel malaria
  • Longer prophylaxis window → adherence challenge for extended travel

Antirelapse Activity — 8-Aminoquinolines Only

Only primaquine and tafenoquine are active against dormant hepatic hypnozoites. Plasmodium vivax and P. ovale establish hypnozoites that can reactivate weeks to years after the initial infection. Radical cure — eradication of the liver reservoir — requires an 8-aminoquinoline course after the blood-stage treatment. G6PD testing is mandatory before prescribing either agent: their oxidative metabolites cause acute hemolytic anemia in G6PD-deficient patients. Tafenoquine (single dose) requires a quantitative G6PD activity test; primaquine requires at least a qualitative screen.

Drug Mechanisms
4-Aminoquinolines
Chloroquine and Hydroxychloroquine
  • Parasites digest hemoglobin in the food vacuole; free heme is released as a toxic byproduct
  • Plasmodium normally polymerizes heme into inert hemozoin crystal (malaria pigment)
  • Chloroquine accumulates in the vacuole (ion trapping) → inhibits heme polymerization → free heme accumulates → parasite dies
  • Resistance: pfcrt K76T exports chloroquine from vacuole before it can accumulate
  • Still active in Central America west of Panama Canal, Haiti, and few other areas
Endoperoxides
Artemisinins
  • Endoperoxide bridge reacts with intraparasitic Fe²⁺ → cytotoxic carbon-centered free radicals
  • Multi-target alkylation of parasite proteins and lipids — including PfKelch13 target
  • Active against ALL blood stages including the ring form — fastest-acting of all antimalarials
  • Very short half-life (~1 hour for artesunate) → always combined with longer-acting partner drug (ACT)
  • IV artesunate: drug of choice for severe falciparum malaria (replaced quinine per AQUAMAT trial)
Mitochondrial Inhibitor
Atovaquone-Proguanil (Malarone)
  • Atovaquone: selectively inhibits parasite cytochrome bc1 (complex III) → collapses mitochondrial membrane potential → ATP synthesis failure
  • Proguanil: active as cycloguanil (DHFR inhibitor); also independently potentiates atovaquone
  • Causal prophylactic — acts on liver stage; stop 7 days after return
  • No G6PD testing required; good tolerability
  • Avoid in severe renal impairment (CrCl <30 mL/min)
Prophylaxis Agent Selection
Agent Type Stop After Return Key Contraindication / Caution
Chloroquine Suppressive 4 weeks Resistant areas (most of the world) — only appropriate in areas with confirmed sensitive P. falciparum
Atovaquone-Proguanil Causal 7 days Severe renal impairment (CrCl <30); limited safety data in pregnancy — use alternative
Doxycycline Causal/Suppressive 4 weeks Contraindicated in pregnancy and children under 8 years; photosensitivity; esophageal ulceration risk
Mefloquine Suppressive 4 weeks Contraindicated with psychiatric history, seizure disorder, cardiac conduction abnormality; FDA black box neuropsychiatric warning; start 2–3 weeks before departure
Primaquine Causal 7 days G6PD deficiency — test before prescribing; contraindicated in pregnancy (fetal G6PD status unknown); hypnozoite eradication only for P. vivax/ovale
Key Toxicities
Chloroquine and Hydroxychloroquine
Retinopathy
  • Accumulates in retinal pigment epithelium → bull's-eye maculopathy
  • Dose-dependent and largely irreversible — damage progresses even after discontinuation
  • Primarily a concern with long-term rheumatologic use (lupus, RA) — short malaria prophylaxis courses rarely cause significant damage
  • Ophthalmology baseline and annual screening recommended per 2016 AAO guidelines for long-term use
  • QTc prolongation — blocks cardiac hERG channel; risk amplified by hypokalemia
8-Aminoquinolines
G6PD-Dependent Hemolytic Anemia
  • Oxidative metabolites generate reactive oxygen species — overwhelm G6PD-deficient red cells lacking adequate glutathione
  • Heinz body formation → intravascular hemolysis → life-threatening anemia if severe deficiency
  • Test G6PD before every prescription — qualitative screen for primaquine; quantitative enzyme assay for tafenoquine
  • Tafenoquine (single dose) is more convenient but riskier in partially deficient patients — requires ≥70% normal G6PD activity

Mefloquine — FDA Black Box Neuropsychiatric Warning and QTc Effects of Quinoline Class

Mefloquine neuropsychiatric effects range from vivid dreams, anxiety, and dizziness to frank psychosis and seizures. The FDA issued a black box warning in 2013 noting that neuropsychiatric adverse events may persist long after drug discontinuation. Mefloquine is absolutely contraindicated in patients with any psychiatric history (depression, anxiety disorder, schizophrenia, PTSD) or active seizure disorder. Because side effects may emerge after the first few doses, travelers should begin mefloquine 2–3 weeks before departure — not just 1 week — to allow time to detect intolerance while still able to switch prophylaxis agents before reaching a remote destination.

The entire quinoline class (quinine, quinidine, mefloquine, halofantrine, lumefantrine, piperaquine) prolongs QTc by blocking the cardiac hERG potassium channel. Risk is highest with intravenous quinine and quinidine — cardiac monitoring is mandatory during parenteral administration. Combining quinoline antimalarials with other QTc-prolonging drugs (fluoroquinolones, macrolides, antipsychotics, ondansetron) amplifies the risk multiplicatively. Correct hypokalemia and hypomagnesemia before and during quinoline therapy.

Resistance Mechanisms
Chloroquine Resistance
pfcrt K76T — Vacuolar Drug Export
  • K76T mutation in the PfCRT transporter converts it from a metabolite channel into an efflux pump for chloroquine
  • Drug is exported from the digestive vacuole before accumulating to toxic levels — heme polymerization proceeds normally
  • Global prevalence: now dominant in sub-Saharan Africa, Southeast Asia, South America, and South Asia
  • Sensitive areas (still use chloroquine): Central America west of Panama Canal, Haiti, Dominican Republic, Middle East
  • Verapamil (calcium channel blocker) reverses resistance in vitro by blocking PfCRT — not clinically used
Artemisinin Partial Resistance
pfkelch13 C580Y — Ring-Stage Dormancy
  • C580Y mutation in PfKelch13 → impairs ubiquitin proteasome activity → parasites slow their metabolic activity during the ring stage
  • Dormant rings survive artemisinin peak exposure, resume development after drug levels fall — "sleeping through" the drug
  • Clinically: delayed parasite clearance (clearance half-life >5 hours vs. <5 hours for sensitive strains)
  • Currently concentrated in Greater Mekong subregion (Cambodia, Thailand, Myanmar); emerging in Rwanda and Uganda
  • When pfkelch13 resistance combines with partner drug resistance → ACT failure → major treatment crisis; WHO emergency response

Suggested References

Author / Source Title Publication
Katzung BG, ed. Basic and Clinical Pharmacology, 15th ed. — Chapter 52: Antiprotozoal Drugs McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 49: Chemotherapy of Malaria McGraw-Hill, 2023
Baird JK, Hoffman SL Primaquine therapy for malaria Clin Infect Dis. 2004;39(9):1336–1345
Miller LH, Baruch DI, Marsh K, Doumbo OK The pathogenic basis of malaria Nature. 2002;415(6872):673–679
World Health Organization Guidelines for the Treatment of Malaria, 3rd ed. WHO; 2015
Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria N Engl J Med. 2019;380(3):215–228
Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance Mol Cell. 2000;6(4):861–871
Marmor MF, Kellner U, Lai TY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision) Ophthalmology. 2016;123(6):1386–1394
Nosten F, White NJ Artemisinin-based combination treatment of falciparum malaria Am J Trop Med Hyg. 2007;77(6 Suppl):181–192
Toovey S Mefloquine neurotoxicity: a literature review Travel Med Infect Dis. 2009;7(1):2–6
Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria Nature. 2014;505(7481):50–55
Dondorp AM, Fanello CI, Hendriksen ICE, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT) Lancet. 2010;376(9753):1647–1657
Schlagenhauf P, Petersen E Malaria chemoprophylaxis: strategies for risk groups Clin Microbiol Rev. 2008;21(3):466–472
Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria N Engl J Med. 2014;371(5):411–423
Brunton L, Knollmann B, Hilal-Dandan R, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 49: Chemotherapy of Malaria McGraw-Hill; 2023